INJECTABLE OPTIONS:
SEMAGLUTIDE GLP-1 AGONIST
TIRZEPATIDE GLP-1 & GIP AGONIST
Chronic Weight Management in Obese/Overweight Adults
Semaglutide's Impact
Semaglutide is classified as GLP-1 receptor agonists, this increases insulin secretion, benefitting diabetics. Appetite is suppressed when higher doses are injected. When used in conjunction with a healthy diet and exercise, Semaglutide assists patients in sticking to a reduced-calorie diet, promoting the weight loss process.
Approved in 2021 by the FDA for chronic weight management in obese/overweight adults, this injection has been described as a ‘game-changer’. “We have not seen this degree of weight loss with any previous medication.” said Dr. Timothy Garvey of the University of Alabama at Birmingham. According to data from trial results, more than 50% of trial participants lost 15% of their body weight and anywhere between a third and 40% of participants lost 20% of their body weight.
RESULTS
In 2021 the FDA approved this injection for chronic weight management
Trial results data shows more than half of the participants lost 15% of their body weight, along with 1/3 of participants losing 20% of their body weight
Dr. Timothy Garvey of the University of Alabama states "We have not seen this degree of weight loss with any previous medication."